Umstellung der hormonalen Kontrazeption auf ein Kombinationspräparat mit antiandrogener Komponente - eine Anwendungsbeobachtung

Abstract

Objective: We conducted an observational study of women who switched to a triphasic oral contraceptive containing norgestimate because of adverse effects with other oral contraceptives. Methods: A total of 1441 current oral contraceptive users were included in the study. All had side effects such as hyperandrogenism, headache and bleeding anomalies, The women switched to a triphasic preparation containing 250 μg norgestimate and 35 μg ethinyl estradiol. The women were assessed before changing the oral contraceptive and 3 and 6 months thereafter. Results: 92.8% of the women completed the study as planned and 7.2% discontinued oral contraception prematurely. The proportion of women with bleeding anomalies decreased by 64.9%. Of the women with acne at study entry, 65% reported complete relief and 19% significant improvement. Of patients with seborrhea, 68% showed complete relief. Conclusion: For oral contraceptive users with side effects, the switch to a triphasic preparation containing norgestimate may significantly improve symptoms such as hyperandrogenism and bleeding problems.